Eliem Therapeutics Provides Update on Pipeline Progress
Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of…
Browsing Tag
Eliem
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of…
Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27,…
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare…
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel…